JP7078555B2 - パントテン酸キナーゼの小分子調節剤 - Google Patents

パントテン酸キナーゼの小分子調節剤 Download PDF

Info

Publication number
JP7078555B2
JP7078555B2 JP2018566834A JP2018566834A JP7078555B2 JP 7078555 B2 JP7078555 B2 JP 7078555B2 JP 2018566834 A JP2018566834 A JP 2018566834A JP 2018566834 A JP2018566834 A JP 2018566834A JP 7078555 B2 JP7078555 B2 JP 7078555B2
Authority
JP
Japan
Prior art keywords
compound
another embodiment
alkyl
halogen
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018566834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518764A5 (enExample
JP2019518764A (ja
Inventor
クマー シャーマ ラリット
イー．リー リチャード
オー．ロック チャールズ
ジャッコウスキ スザンヌ
キョン ユン ミー
サブラマニアン チトラ
リウ チウユイ
Original Assignee
セント ジュード チルドレンズ リサーチ ホスピタル，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60783428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7078555(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by セント ジュード チルドレンズ リサーチ ホスピタル，インコーポレイティド filed Critical セント ジュード チルドレンズ リサーチ ホスピタル，インコーポレイティド
Publication of JP2019518764A publication Critical patent/JP2019518764A/ja
Publication of JP2019518764A5 publication Critical patent/JP2019518764A5/ja
Application granted granted Critical
Publication of JP7078555B2 publication Critical patent/JP7078555B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018566834A 2016-06-23 2017-06-23 パントテン酸キナーゼの小分子調節剤 Active JP7078555B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662354012P 2016-06-23 2016-06-23
US62/354,012 2016-06-23
PCT/US2017/039037 WO2017223474A1 (en) 2016-06-23 2017-06-23 Small molecule modulators of pantothenate kinases

Publications (3)

Publication Number Publication Date
JP2019518764A JP2019518764A (ja) 2019-07-04
JP2019518764A5 JP2019518764A5 (enExample) 2020-08-06
JP7078555B2 true JP7078555B2 (ja) 2022-05-31

Family

ID=60783428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018566834A Active JP7078555B2 (ja) 2016-06-23 2017-06-23 パントテン酸キナーゼの小分子調節剤

Country Status (14)

Country Link
US (2) US10899734B2 (enExample)
EP (1) EP3474667A4 (enExample)
JP (1) JP7078555B2 (enExample)
KR (1) KR102459256B1 (enExample)
CN (1) CN109561680B (enExample)
AU (1) AU2017281907B2 (enExample)
CA (1) CA3025260A1 (enExample)
DO (1) DOP2018000293A (enExample)
IL (1) IL263649B (enExample)
MX (1) MX383697B (enExample)
SA (1) SA518400696B1 (enExample)
SG (1) SG11201811023UA (enExample)
WO (1) WO2017223474A1 (enExample)
ZA (1) ZA201808099B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383697B (es) 2016-06-23 2025-03-14 St Jude Childrens Res Hospital Inc Moduladores de moleculas peque?as de pantotenato cinasas
KR102728619B1 (ko) * 2017-12-27 2024-11-08 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 판토테네이트 키나제의 소분자 조절제
CA3086711A1 (en) * 2017-12-27 2019-07-04 St. Jude Children's Research Hospital, Inc. Use of arylpiperazine-1-carboxamide derivatives in the treatment of coenzyme a-mediated disorders
JPWO2020017569A1 (ja) * 2018-07-17 2021-12-02 日本ケミファ株式会社 Ｔ型カルシウムチャネル阻害剤
EP3946312A4 (en) * 2019-03-27 2023-04-19 St. Jude Children's Research Hospital SMALL MOLECULE MODULATORS OF PANK
WO2020203609A1 (ja) * 2019-03-29 2020-10-08 日本ケミファ株式会社 掻痒を治療するためのｔ型カルシウムチャネル阻害剤の使用
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
EP4262814A4 (en) * 2020-12-16 2025-02-26 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor
TW202417421A (zh) * 2022-08-08 2024-05-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之雜環醯胺及脲化合物
CN119745886A (zh) * 2025-01-20 2025-04-04 中国药科大学 4-异丙苯基乙酰哌嗪在制备抗阿尔茨海默病药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513969A (ja) 2003-12-09 2007-05-31 ケモセントリックス インコーポレーティッド 置換ピペラジン
JP2011528329A (ja) 2008-07-18 2011-11-17 ノバルティス アーゲー Ｓｍｏ阻害剤としてのピリダジン誘導体
JP2014518240A (ja) 2011-07-01 2014-07-28 リマインド・ナムローゼ・フエンノートシャップ 神経変性疾患の治療に有用な１，２，４−チアジアゾール−５−イルピペラジン誘導体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894063B2 (en) * 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
EP1322628A2 (en) * 2000-09-14 2003-07-02 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
AU2003236500B9 (en) * 2002-06-12 2009-07-02 Chemocentryx, Inc. 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
AR044688A1 (es) 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
JP4831577B2 (ja) * 2003-07-30 2011-12-07 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピリダジン誘導体および治療剤としての用途
US20060035884A1 (en) 2004-05-20 2006-02-16 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
CA2668811A1 (en) 2006-11-07 2008-06-05 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
CA2690378A1 (en) 2007-06-25 2008-12-31 Amgen Inc. Phthalazine compounds, compositions and methods of use
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
CA2873097A1 (en) 2012-05-11 2013-11-14 Todd M. Hansen Pyridazine and pyridine derivatives as nampt inhibitors
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
CN107922377A (zh) 2015-04-17 2018-04-17 美国印第安纳大学研究和技术公司 乙肝病毒组装效应子
MX383697B (es) 2016-06-23 2025-03-14 St Jude Childrens Res Hospital Inc Moduladores de moleculas peque?as de pantotenato cinasas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513969A (ja) 2003-12-09 2007-05-31 ケモセントリックス インコーポレーティッド 置換ピペラジン
JP2011528329A (ja) 2008-07-18 2011-11-17 ノバルティス アーゲー Ｓｍｏ阻害剤としてのピリダジン誘導体
JP2014518240A (ja) 2011-07-01 2014-07-28 リマインド・ナムローゼ・フエンノートシャップ 神経変性疾患の治療に有用な１，２，４−チアジアゾール−５−イルピペラジン誘導体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY (STN) RN 1954499-65-0, [online]，2016年07月18日，[Retrieved on 2021.04.06］
DATABASE REGISTRY (STN) RN 1956298-43-3, [online]，2016年07月20日，[Retrieved on 2021.04.06]
Pubmed Compound Summary for CID 110727414, U.S. National Library of Medicine，2016年01月18日，https://pubchem.ncbi.nlm.nih.gov/compound/110727414
Tafesse, Laykea et al.，Bioorganic & Medicinal Chemistry Letters，2004年，Vol.14, No.22，p.5513-5519

Also Published As

Publication number Publication date
EP3474667A1 (en) 2019-05-01
IL263649A (en) 2019-01-31
RU2019101613A3 (enExample) 2020-12-03
DOP2018000293A (es) 2019-04-15
NZ749147A (en) 2024-04-26
RU2019101613A (ru) 2020-07-23
IL263649B (en) 2022-04-01
CA3025260A1 (en) 2017-12-28
AU2017281907A1 (en) 2019-01-03
KR20190022620A (ko) 2019-03-06
MX383697B (es) 2025-03-14
SG11201811023UA (en) 2019-01-30
AU2017281907B2 (en) 2021-10-21
JP2019518764A (ja) 2019-07-04
ZA201808099B (en) 2019-07-31
CN109561680B (zh) 2021-07-13
US20210246113A1 (en) 2021-08-12
EP3474667A4 (en) 2019-11-27
BR112018076441A2 (pt) 2019-04-09
SA518400696B1 (ar) 2023-01-09
US10899734B2 (en) 2021-01-26
US20190300499A1 (en) 2019-10-03
KR102459256B1 (ko) 2022-10-25
CN109561680A (zh) 2019-04-02
WO2017223474A1 (en) 2017-12-28
MX2018015170A (es) 2019-07-04

Similar Documents

Publication Publication Date Title
JP7078555B2 (ja) パントテン酸キナーゼの小分子調節剤
JP6147727B2 (ja) チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
EP1442019B1 (en) Amide derivatives as glycogen synthase kinase 3-beta inhibitors
US9296703B2 (en) Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
US9550778B2 (en) Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
JP7352565B2 (ja) パントテン酸キナーゼの小分子モジュレーター
EP2477492A1 (en) Substituted heteroarylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
US8969389B2 (en) Substituted 6-methylnicotinamides as mGluR5 positive allosteric modulators
JP2013505297A (ja) ｍＧｌｕＲ５の正のアロステリック調節因子としてのＯ−ベンジルニコチンアミド類似体
BR112020026337A2 (pt) Compostos tricíclicos
RU2764652C2 (ru) Низкомолекулярные модуляторы пантотенаткиназ
HK40006981A (en) Small molecule modulators of pantothenate kinases
US20250026743A1 (en) Heteroaryl-linked analogs as mglu5 negative allosteric modulators and methods of making and using the same
BR112018076441B1 (pt) Moduladores de molécula pequena de pantotenato quinases e seus usos
RU2797123C2 (ru) Низкомолекулярные модуляторы пантотенаткиназ
WO2025137146A1 (en) Substituted heteroaryl analogs and uses thereof for the treatment of hiv-associated neurocognitive disorders
KR20250096635A (ko) Tyk2 억제제 및 이의 용도
HK40006981B (zh) 泛酸激酶的小分子调节剂
CN119343143A (zh) 含硼嘧啶化合物、包含它们的组合物、其方法和用途
AU2022345066A1 (en) Phenyl core compounds as mglu5 negative allosteric modulators and methods of making and using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200623

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220519

R150 Certificate of patent or registration of utility model

Ref document number: 7078555

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250